Associate Professor Ashton’s lab focuses on the endocannabinoid system. Discovered less than two decades ago, this system of receptors, messengers, and enzymes regulates a number of physiological processes. Cannabinoid drugs act on this system with a variety of effects, some of therapeutic benefit, and some potentially harmful. His research interests include cannabinoid drugs, neurodegeneration, neuroinflammation, hyperalgesia and pain, interactions of cannabinoids with selective serotonin reuptake inhibitors, cannabinoid CB2 receptors as drug targets, and endocannabinoid signaling.
Associate Professor Ashton is looking at the endocannabinoid system to better understand how it functions and to tease out the beneficial effects from the side effects of new cannabinoid drugs. He and other research groups have recently found the CB2 receptor to be involved in a number of pathological processes in the central nervous system. He is focusing on ischemic brain damage (stroke) and chronic, neuropathic pain; two major medical problems that cause enormous social costs and carry a huge burden of individual suffering.
Along with collaborating labs in Auckland and the USA, he has found exciting preliminary data that shows that drugs that can activate the CB2 receptor can reduce brain damage from stroke and relieve chronic pain from nerve injuries.
Find out more about Associate Professor Ashton’s research
Publications
Rivers-Auty, J. R., Smith, P. F., & Ashton, J. C. (2014). The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in rats. Neuroscience Letters, 569, 104-109. doi: 10.1016/j.neulet.2014.03.077
Maggo, S., & Ashton, J. C. (2014). Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig. European Journal of Pharmacology, 723, 294-304. doi: 10.1016/j.ejphar.2013.11.018
Ashton, J. C., Zheng, Y., Darlington, C., Baek, J.-H., & Smith, P. F. (2014). Cannabinoid CB2 receptor immunolabelling in the healthy brain—still a live possibility. Naunyn-Schmiedeberg's Archives of Pharmacology, 387(3), 301. doi: 10.1007/s00210-013-0948-y
Rivers-Auty, J., & Ashton, J. C. (2014). Neuroinflammation in ischemic brain injury as an adaptive process. Medical Hypotheses, 82(2), 151-158. doi: 10.1016/j.mehy.2013.11.024
Linsell, O., & Ashton, J. C. (2014). Cerebral hypoxia-ischemia causes cardiac damage in a rat model. NeuroReport, 25(10), 796-800. doi: 10.1097/wnr.0000000000000190
Rivers-Auty, J. R., Smith, P. F., & Ashton, J. C. (2014). The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in rats. Neuroscience Letters, 569, 104-109. doi: 10.1016/j.neulet.2014.03.077
Journal - Research Article
Maggo, S., & Ashton, J. C. (2014). Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig. European Journal of Pharmacology, 723, 294-304. doi: 10.1016/j.ejphar.2013.11.018
Journal - Research Article
Ashton, J. C., Zheng, Y., Darlington, C., Baek, J.-H., & Smith, P. F. (2014). Cannabinoid CB2 receptor immunolabelling in the healthy brain—still a live possibility. Naunyn-Schmiedeberg's Archives of Pharmacology, 387(3), 301. doi: 10.1007/s00210-013-0948-y
Journal - Professional & Other Non-Research Articles
Rivers-Auty, J., & Ashton, J. C. (2014). Neuroinflammation in ischemic brain injury as an adaptive process. Medical Hypotheses, 82(2), 151-158. doi: 10.1016/j.mehy.2013.11.024
Journal - Research Other
Linsell, O., & Ashton, J. C. (2014). Cerebral hypoxia-ischemia causes cardiac damage in a rat model. NeuroReport, 25(10), 796-800. doi: 10.1097/wnr.0000000000000190
Journal - Research Article
Marchalant, Y., Brownjohn, P. W., Bonnet, A., Kleffmann, T., & Ashton, J. C. (2014). Validating antibodies to the cannabinoid CB2 receptor: Antibody sensitivity is not evidence of antibody specificity. Journal of Histochemistry & Cytochemistry, 62(6), 395-404. doi: 10.1369/0022155414530995
Journal - Research Article
Brownjohn, P. W., & Ashton, J. C. (2014). What can be concluded from blocking peptide controls? Applied Immunohistochemistry & Molecular Morphology, 22(8), 634. doi: 10.1097/PAI.0b013e3182a77fe5
Journal - Research Other
Ashton, J. C. (2013). Experimental power comes from powerful theories: The real problem in null hypothesis testing. Nature Reviews Neuroscience, 14, 585. doi: 10.1038/nrn3475-c2
Journal - Research Other
Rivers, J. R., & Ashton, J. C. (2013). Neonatal asphyxia and stroke: Morbidity, models, consequences, and treatments. In D. Vordermark (Ed.), Hypoxia: Causes, types and management. (pp. 89-110). New York: Nova.
Chapter in Book - Research
Rivers, J. R., & Ashton, J. C. (2013). Age matching animal models to humans: Theoretical considerations. Current Drug Discovery Technologies, 10(3), 177-181.
Journal - Research Article
Baek, J.-H., Darlington, C. L., Smith, P. F., & Ashton, J. C. (2013). Antibody testing for brain immunohistochemistry: Brain immunolabeling for the cannabinoid CB2 receptor. Journal of Neuroscience Methods, 216(2), 87-95. doi: 10.1016/j.jneumeth.2013.03.021
Journal - Research Article
Rivers-Auty, J., & Ashton, J. C. (2013). Vehicles for lipophilic drugs: Implications for experimental design, neuroprotection, and drug discovery. Current Neurovascular Research, 10(4), 356-360. doi: 10.2174/15672026113109990021
Journal - Research Other
Ashton, J. C. (2013). Phylogenetic methods in drug discovery. Current Drug Discovery Technologies, 10(4), 255-262. doi: 10.2174/15701638113109990033
Journal - Research Article
Brownjohn, P. W., & Ashton, J. C. (2012). Spinal cannabinoid CB2 receptors as a target for neuropathic pain: An investigation using chronic constriction injury. Neuroscience, 203, 180-193. doi: 10.1016/j.neuroscience.2011.12.028
Journal - Research Article
Ashton, J. C., Mockett, B., & Maggo, S. D. S. (2012). Cholesterol lowering through HMG CoA reductase inhibitors (statins) impairs long term potentiation and induces anxiety in guinea pigs. Proceedings of the Australian Neuroscience Society (ANS) Annual Scientific Meeting. (pp. 78). Retrieved from http://www.ans.org.au/ans-annual-conference/
Conference Contribution - Published proceedings: Abstract
Brownjohn, P. W., & Ashton, J. C. (2012). A technical note for improving animal welfare and model validity in the chronic constriction injury model of neuropathic pain. European Journal of Pain, 16(10), 1477. doi: 10.1002/j.1532-2149.2012.00199.x
Journal - Research Other
Maggo, S., Clark, D., & Ashton, J. C. (2012). The effect of statins on performance in the Morris water maze in guinea pig. European Journal of Pharmacology, 674(2-3), 287-293. doi: 10.1016/j.ejphar.2011.11.006
Journal - Research Article
Breen, C., Brownjohn, P. W., & Ashton, J. C. (2012). The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. Neuroscience Letters, 508(2), 119-122. doi: 10.1016/j.neulet.2011.12.039
Journal - Research Article
Mandhane, S., Nayak, P., Soni, D., Jain, S., Ashton, J. C., & Rajamannar, T. (2012). Induction of glucose intolerance by acute administration of rimonabant. Pharmacology, 89(5-6), 339-347. doi: 10.1159/000337731
Journal - Research Article
Ashton, J. C. (2012). The use of knockout mice to test the specificity of antibodies for cannabinoid receptors. Hippocampus, 22(3), 643-644. doi: 10.1002/hipo.20946
Journal - Research Other
Brownjohn, P. W., Ashton, J. C., & Chase, J. G. (2012). Microglial encapsulation of motor neurons in models of neuropathic pain: A confound in pain assessment? European Journal of Pain, 16(3), 459-460. doi: 10.1002/j.1532-2149.2011.00101.x
Journal - Research Other
Ashton, J. C. (2012). Neuropathic pain: An evolutionary hypothesis. Medical Hypotheses, 78(5), 641-643. doi: 10.1016/j.mehy.2012.01.044
Journal - Research Article
Rivers, J. R., Maggo, S. D. S., & Ashton, J. C. (2012). Neuroprotective effect of hydroxypropyl-β-cyclodextrin in hypoxia-ischemia. NeuroReport, 23(3), 134-138. doi: 10.1097/WNR.0b013e32834ee47c
Journal - Research Article
Ashton, J. C. (2012). Synthetic cannabinoids as drugs of abuse. Current Drug Abuse Reviews, 5(2), 158-168. doi: 10.2174/1874473711205020158
Journal - Research Article
Ashton, J. C. (2012). The atypical cannabinoid O-1602: Targets, actions, and the central nervous system. Central Nervous System Agents in Medicinal Chemistry, 12(3), 233-239.
Journal - Research Article
Maggo, S. D. S., Mockett, B. G., & Ashton, J. C. (2012). The effects of chronic statin administration: Assessment of hippocampal spatial memory and long term potentiation in area CA1. Proceedings of the Medical Sciences Congress (MedSci). (pp. 24-25). Retrieved from http://www.medscinz.co.nz/QRW2012%20MedSci%20Abstracts.pdf
Conference Contribution - Published proceedings: Abstract
Ashton, J. C. (2015). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research, 75, 2400. doi: 10.1158/0008-5472.can-14-3763
Journal - Research Other